Aim: To investigate the effects of semaglutide on fasting and postprandial glucose and lipid responses, and on gastric emptying.
| INTRODUCTION
Type 2 diabetes (T2D) is a progressive metabolic disease with increasing prevalence. 1 T2D is characterized by chronic hyperglycaemia caused by insulin resistance or reduced insulin secretion. 1, 2 Despite the availability of several anti-diabetic drugs, there remains an unmet need for better therapies because a significant proportion of individuals with T2D do not achieve recommended treatment targets for glycaemic control. 3 Inadequately controlled T2D can result in various complications, including an increased risk of cardiovascular disease. 1 Hyperlipidaemia often co-exists with T2D and is a clear risk factor for atherosclerotic cardiovascular disease. 4 Controlling hyperlipidaemia is one of the central recommendations of the American Heart Association to reduce the risk of cardiovascular disease. 5 Glucagon-like peptide-1 (GLP-1) and peptide PYY (PYY) are gut hormones, colocalized in intestinal L cells, that are released in response to nutrient intake. 6, 7 GLP-1 stimulates insulin secretion and inhibits glucagon secretion in a glucose-dependent manner. 8 At physiological levels, GLP-1 is also associated with an inhibitory effect on gastric emptying and with lowering of body weight, as the result of reduced appetite and decreased energy intake. [8] [9] [10] [11] These properties have led to the development of GLP-1 receptor agonists (GLP-1RAs) as a treatment option for individuals with T2D, with one GLP-1RA also developed for the treatment of obesity. 12 GLP-1RAs have been associated with improved beta-cell function, 13, 14 and have been shown to lower postprandial glucose levels and reduce lipid responses. [15] [16] [17] [18] In addition, GLP-1RAs have the potential to affect gastric emptying, 19 with an apparently diminished response over time with long-acting GLP-1RAs. 20 Semaglutide is a human GLP-1 analogue currently in development for once-weekly treatment of T2D. Semaglutide has 94% structural homology with native human GLP-1 21, 22 with 3 important modifications:
an amino acid substitution at position 8 that makes it less susceptible to degradation by dipeptidyl peptidase-4; lysine acylation of the peptide backbone, with a spacer and C-18 fatty di-acid chain at position 26 that provides strong, specific binding to albumin; and another amino acid substitution at position 34, which prevents C-18 fatty di-acid binding at the wrong site. 21 These modifications give semaglutide an extended half-life of approximately 1 week, 21 making it suitable for once-weekly administration, 23, 24 which has the potential for improving patient compliance and quality of life, 22 compared with first-generation GLP-1RAs that require once-or twice-daily dosing. 25 Semaglutide is associated with dose-dependent reductions in glycated haemoglobin (HbA1c) levels and body weight in individuals with diabetes. 26 Previously, we reported that semaglutide, compared with placebo, reduced body weight and ad libitum energy intake after 12 weeks of treatment. 27 This finding was supported by different aspects of homeostatic and hedonic appetite parameters. 27 Here, we report data from the same study on the effects of semaglutide, compared with placebo, on fasting and postprandial glucose and lipid responses, as well as its effects on gastric emptying.
| MATERIALS AND METHODS

| Study design
Details of the study design have been described elsewhere. 27 Briefly, this was a single-centre, randomized, double-blind, 2-period, placebo- 
| Assessments and endpoints
At the end of each 12-week treatment period, on Fasting values and paracetamol endpoints were analyzed using a linear mixed model on log-transformed data, including treatment and treatment period as fixed effects and subject as random effect. Incremental area under the concentration-time curves (iAUC) of glycaemic and lipid parameters were analyzed using a linear mixed model, including treatment and treatment period as fixed effects, fasting value as covariate and subject as random effect.
Four subjects did not complete the standardized carbohydraterich breakfast during the second treatment period (17%-40% of meals not eaten) and were excluded from the statistical analyses of endpoints related to this meal test, with the exception of the data points relating to gastric emptying, as all subjects consumed the paracetamol-containing yoghurt. Two subjects did not complete the standardized fat-rich breakfast and were excluded from the statistical analyses of endpoints relating to this meal test. A sensitivity analysis of gastric emptying was done for the 4 subjects who did not complete the standardized breakfast but who consumed the paracetamolcontaining yoghurt, as well as for 1 subject who, on one occasion, received placebo rather than semaglutide, and 1 subject who had a measurable plasma paracetamol concentration at baseline. Furthermore, sensitivity analyses were performed for glucose and TG endpoints for the 1 subject who received placebo rather than semaglutide on 1 occasion. Findings from the sensitivity analyses supported the overall results.
The effects of gastric emptying on first-hour postprandial glucose absorption were assessed in an exploratory analysis of glucose results, from the same meal as when the paracetamol sampling was performed. Glucose measured before and up to 1 hour after the standardized breakfast (AUC 0-1h for glucose) was further analyzed, with or without adjustment for the subject-mean-centred log-transformed AUC 0-1h for paracetamol concentration as covariate.
3 | RESULTS
| Subject characteristics
A total of 30 subjects were randomized to once-weekly semaglutide or placebo. At baseline, mean (standard deviation) age, body weight, height and BMI were 42 (11) Figure S1 , Table 1 ).
| Insulin and C-peptide
At the end of the 12-week treatment period, subjects receiving semaglutide had significantly higher mean fasting concentrations of insulin and C-peptide compared with those receiving placebo (ETR: Figure S1 , Table 1 ).
Before the fat-rich breakfast, subjects treated with semaglutide also had higher fasting concentrations of insulin and C-peptide, although this was only borderline significant for insulin difference in postprandial increments (iAUC 0-5h ) for glucagon between semaglutide and placebo ( Figure 1 , Table 1 ).
Before and following the standardized fat-rich breakfast, fasting
and postprandial values (iAUC 0-8h ) for glucagon tended to be lower with semaglutide than with placebo (−13% and −27.3%, respectively) ( Figure S1 , Table 1 ).
| Lipid metabolism
Fasting total cholesterol and HDL cholesterol were lower with sema- Table 2 ). No difference in FFA was observed.
| Gastric emptying
As assessed by paracetamol concentrations, gastric emptying during the first hour, following the standardized carbohydrate-rich breakfast, 
| Effect of gastric emptying on glucose response
Following the standardized carbohydrate-rich breakfast, the postprandial increment for glucose within the first hour (iAUC 0-1h ) was 37.8% lower with semaglutide than with placebo (ETD: 
| PYY response
At the end of the 12-week treatment period, subjects receiving sema- 
19,31
Following 12 weeks of treatment with semaglutide, there were generally lower postprandial increments of glucose-related parameters, including glucose, glucagon, insulin and C-peptide. However, the differences in glucose parameters were less pronounced between treatments following the fat-rich breakfast, possibly as a result of the expected reduction in glucose absorption associated with a high fat intake, 32 and/or the lower absolute amount of carbohydrate in the fatrich breakfast vs the carbohydrate-rich breakfast (50 g vs 83 g). 33 Our findings in a population with obesity, but not T2D, are in alignment with results from previous studies with GLP1RAs. [15] [16] [17] 34, 35 Liraglutide has been shown to significantly reduce mean postprandial glucose and glucagon (AUC 0-5h ) compared with placebo, both in subjects with T2D, 15 and in obese, non-diabetic adults. 35 Similarly, albiglutide and dulaglutide, both of which are once-weekly GLP-1RAs, have been shown to lower fasting and postprandial glucose concentrations. 17, 34 In relation to glycaemic control, GLP-1RAs increase insulin secretion in a glucose-dependent manner, Placebo (n = 28)
Mean lipid metabolism profiles after standardized, fat-rich breakfast. Error bars represent standard error. Abbreviation: VLDL, verylow-density lipoprotein suppress glucagon and slow gastric emptying, which affects the postprandial glucose response. 13, 14, 19 The observed reduction in postprandial insulin and C-peptide in this trial may be explained, in part, by the reduction in glucose concentrations observed after 12 weeks of treatment. It is conceivable that semaglutide may produce a greater response in subjects with T2D with higher glycaemia. 15, 35, 36 In another 12-week study with semaglutide in subjects with T2D, a pronounced improvement of beta-cell function was shown, and the impact on 24-hour glucose, insulin and C-peptide responses during a test day with 3 standardized meals was similar to observations in the current study. 36 The effects of semaglutide on insulin and glucose are interdependent. In the fasting state, the concentrations of insulin and C-peptide are significantly increased. However, after 12 weeks of treatment, in the postprandial state the lower insulin increments should be interpreted in light of the concurrent lower glucose increments.
Previously we reported an observed body weight reduction of 5.0 kg following 12 weeks of semaglutide treatment. 27 Body weight loss is known to improve insulin sensitivity. 37 Improved insulin sensitivity would result in a decrease in glucose concentrations and, thus, less insulin demand. Therefore, weight loss reported in this study Our study is the first to investigate the effect of semaglutide treatment on postprandial lipid absorption and metabolism. Following a standardized fat-rich breakfast, subjects treated with semaglutide had lower postprandial TG, VLDL and ApoB-48 over 8 hours (iAUC 0-8h ). Postprandial ApoB-48, a marker of TG uptake from the gut, is known to be involved in the assembly of chylomicron particles required for the absorption of TGs. 39 Chylomicron production has been shown to be increased in subjects with T2D and insulin resistance. 39 In reduced ApoB-48 production and increased ApoB-48 catabolism. 41 The frequency of obesity is reported to be greater in consumers of high-fat diets than in consumers of low-fat diets. 42 Therefore, the demonstrable effect of semaglutide on blood lipids during a high-fat meal is highly relevant for subjects with obesity, who often consume energy-dense, high-fat foods that contribute to hyperlipidaemia.
In our study, fasting concentrations of TG and VLDL were also significantly lower with semaglutide than with placebo. In addition, total cholesterol and HDL cholesterol were lower with semaglutide than with placebo, whereas LDL cholesterol appeared to be comparable between treatments. In longer-term studies with semaglutide, 1 to 2 years of treatment modestly improved various lipid parameters in subjects with T2D compared with placebo or treatment with sitagliptin. 43, 44 These findings are consistent with those for other GLP1RAs, including liraglutide and exenatide. 18, 45, 46 Hyperlipidaemia is a well-known risk factor for cardiovascular diseases. 47, 48 Thus, lowering serum TGs may reduce the risk of cardiovascular diseases such as atherosclerosis. 5 In particular, lowering of non-fasting TG could be of clinical importance as higher concentrations have been shown to be associated with an increased risk of myocardial infarction, ischaemic heart disease and death. 48 The effect of semaglutide on cardiovascular outcomes in subjects with T2D has been reported in the 2-year SUSTAIN 6 study. 44 Results from this study showed that, among subjects with T2D at high cardiovascular risk, the rate of first occurrence of death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke was significantly lower in those receiving semaglutide than in those receiving placebo. 44 The effect of semaglutide on postprandial glucose and lipid metabolism may have contributed to these findings.
GLP-1RAs have the capacity to slow gastric emptying in a variable but marked manner, when administered acutely, which may represent a key mechanism contributing to their glucose-lowering effect. 19 However, some investigations indicate that this phenomenon is transient and the effect on gastric emptying diminishes over time. 49, 50 The differing durations of action of GLP-1RAs seem to influence gastric emptying with continued dosing. The slowing of gastric emptying induced by several long-acting GLP-1 agonists 49, 51 (although not by exenatide twice daily or lixisenatide) lessens with time, perhaps indicative of adaptation over time. 19 In our study, after 12 weeks of treatment, there was no statistically significant difference between semaglutide and placebo for the overall rate of postprandial gastric emptying. A delayed gastric emptying response was detected during the first hour after the standardized breakfast compared with placebo. This finding is consistent with previous findings for liraglutide. 18, 19 Gastric emptying during the first hour was a significant covariate in the statistical analysis of postprandial glucose response following the standardized breakfast, indicating that approximately 40% of the initial glucose response could be explained by the rate of gastric emptying, and that gastric emptying contributed to the lower postprandial increase in glucose response observed when subjects were treated with semaglutide.
We used the paracetamol absorption test to measure the rate of gastric emptying. Although it provides an indirect estimation of gastric emptying, this technique is reported to correlate generally well with scintigraphy. 52 A limitation with all gastric emptying tests is the considerable inter-individual variation; 52 however, this was counteracted by intra-subject comparisons in this study. Despite claimed limitations in drawing conclusions about solids from paracetamol studies, 52 it should be noted that paracetamol in this study was added to the semi-solid part of the meal (yoghurt). In a previous study investigating the effect of liraglutide on gastric emptying, 18 a comparable set-up was used and similar results were observed with the paracetamol test and the octanoate breath test (labelling the solid part of the meal) during the same meal. Furthermore, the results on gastric emptying obtained in the current study agree with observations in other long-acting GLP-1RA studies. 53, 54 The lower PYY response observed with semaglutide is in align- The strengths of this study include the crossover design, with subjects serving as their own control, the high degree of standardization, and the frequency of sampling, up to 5 and 8 hours after the standardized meals. A potential weakness is that, of those subjects receiving semaglutide, 4 did not ingest all of the standardized breakfast meal (consuming approximately 60%-83%) and, likewise, 2 subjects consumed only part of the standardized fat-rich breakfast.
Therefore, related data derived from these subjects were excluded from the glucose and TG results. Nevertheless, sensitivity analyses confirmed the results from the primary analyses.
To conclude, fasting and postprandial glucose and lipid metabolism were improved after 12 weeks of treatment with semaglutide compared with placebo. Overall, 5 hours postprandial gastric emptying was similar for semaglutide and placebo; with semaglutide, however, a delay was observed during the first hour after a meal, possibly contributing to a slower entry of glucose into the circulation.
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